Gene-level Regulation Analysis of Cancer Glucose Metabolism

Gene-level Regulation Analysis of Cancer Glucose Metabolism

Gene-level Regulation Analysis of Cancer Glucose Metabolism

Glucose energy conversion is mainly through oxidative phosphorylation, glycolysis, and pentose phosphate pathways. Research in the field of tumor metabolism can be roughly divided into three major metabolic regulations in tumors, reprogramming, epigenetic modification of metabolites, changes in metabolism-related signaling pathways, and interactions between metabolic regulatory genes and oncogenes. It has been confirmed that several genes can regulate tumor metabolism, including genes that regulate tumor glucose metabolism, oncogenes, and tumor suppressors. The study of glucose metabolism-related genes to regulate the reprogramming of glucose metabolism and the correction of abnormal cell metabolism has become a new idea for preventing the occurrence and development of tumors and treating tumors. CD BioGlyco can provide gene-level regulatory analysis of cancer glucose metabolism.

Why Analyze the Regulation of Cancer Glucose Metabolism at the Gene Level?

Gene mutation has become an important factor in tumorigenesis, and the mutual regulation of cellular glucose metabolism and gene expression is characteristic of tumor cells. Although cancer cell metabolism is regulated by glucose metabolic enzymes in metabolic pathways, glucose metabolic enzymes are directly regulated by metabolism-related genes.

Our MOPCGM platform enables the study of the link between oncogenes, tumor suppressors and glucose metabolism, non-coding RNAs, epigenetics, and other mechanisms of glucose metabolism regulation. The above information provides new ideas for researchers in the field of biological sciences, pharmaceutical R&D companies, etc. to prevent the occurrence and development of tumors and treat tumors by targeting the glucose metabolism process of cancer cells and correcting abnormal cell metabolism.

What We Do


Our services can support the following applications, including but not limited to:

  • Reprogramming of glucose metabolism in cancer cells by correcting gene mutations by gene therapy or gene editing.
  • Epigenetic drug development targeting the process of glucose metabolism in cancer.

CD BioGlyco can provide gene-level analysis of the reprogramming of cancer glucose metabolism, which is mainly divided into the analysis of the roles of oncogenes, tumor suppressors, non-coding RNAs and epigenetic modifications in the regulation of cancer glucose metabolism. Our experienced teams of scientists, researchers, and technicians provide fast turnaround, high-quality services at competitive prices for worldwide customers. Our customers have direct access to our staff and prompt feedback on their inquiries. If you are interested in our services, please contact us for more details.

This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.